The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion spotlighted three major themes that shaped this year's American Diabetes Association (ADA) gathering as ADA2026 came to a close.
The company reflected on the dynamic conversations, novel research, and innovative approaches that characterized the conference. Team Fusion underscored these themes as central to advances in diabetes science and patient care shared during the event. Further details on the three highlighted themes are available through Biomea Fusion official communications. Details are being clarified.
Biomea Fusion recently announced new data for icovamenib in type 1 and type 2 diabetes, reporting sustained improvements in insulin secretion and metabolic health in both groups here. Earlier, the company visited clinical study sites to advance Phase II trials of icovamenib in type 2 diabetes here. Both developments highlight ongoing research efforts around the company’s diabetes pipeline.